Fate Therapeutics, Inc. (FATE)

Over the past six months, Fate Therapeutics' stock price has been impacted by several events. The stock price experienced a decline of 45.91% between October 24, 2024, and October 23, 2025. As of June 12, 2025, the stock was reported to be up 61.5% since its last earnings report. In May 2025, Barclays issued an "Overweight" rating with a $2.0 price target, and Baird set a target price of $4.0. Fate Therapeutics reported its Q2 2025 financial results, showing a loss but beating revenue estimates. In August 2025, Wells Fargo & Company lowered its price target for Fate Therapeutics from $4.00 to $2.50. On October 20, 2025, Kamal Adawi was appointed as the new Chief Financial Officer. The company has disclosed a risk of Nasdaq delisting. In October 2025, Fate Therapeutics announced promising Phase 1 clinical trial results for FT819 in treatment-refractory Systemic Lupus Erythematosus (SLE). Insider trading activity in the past six months included sales by the President and CEO, and the Chief Legal and Compliance Officer. In March 2025, the company initiated Phase 1 dose expansion for FT819 in SLE using a fludarabine-free conditioning regimen. Updated data from the Phase 1 study of FT819 in autoimmune disease was reported in June 2025.

As a clinical-stage biopharmaceutical company, Fate Therapeutics, Inc. does not have traditional "products and services" that are subject to demand seasonality. Its revenue is primarily derived from collaborations and grants, rather than product sales. Any mention of seasonality for FATE typically refers to stock market trends rather than seasonal fluctuations in product demand. Historical data suggests that October has historically favored a short bias for FATE's stock.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation cellular immunotherapies for cancer and immune disorders, operating within the Health Technology sector and Biotechnology industry. Fate Therapeutics utilizes a proprietary induced pluripotent stem cell (iPSC) product platform to engineer "off-the-shelf" natural killer (NK) and T-cell product candidates, designed to be universally available. FT516 is for acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors. FT596 is to treat B-cell lymphoma and chronic lymphocytic leukemia. FT538 is for AML and multiple myeloma. FT576 is to treat multiple myeloma. FT819 is for hematologic malignancies, solid tumors, and treatment-refractory systemic lupus erythematosus (SLE). FT536 is to treat solid tumors. FT500 is for advanced solid tumors. FT522 is for lymphoma and autoimmune disorders. FT825 is for advanced solid tumors. FT836 has potential in multiple tumors.

Fate Therapeutics, Inc. is headquartered in San Diego, California, United States. The company's impact and operations are global, conducting clinical trials for its iPSC-derived cell therapies in multiple countries and collaborating with international research institutions and clinical sites. The company also has offices in Canada, the Netherlands, and the United Kingdom.

Fate Therapeutics maintains a focus on corporate responsibility, which contributes to its brand reputation. This includes community engagement through supporting autoimmune and cancer research, as well as STEM education initiatives. The company also emphasizes employee health and safety, environmental sustainability, adherence to clinical trial standards, drug quality and safety, ethics and compliance, governance, and cybersecurity. Recent positive events impacting its reputation include the announcement of promising Phase 1 clinical trial results for FT819 in SLE. The appointment of Kamal Adawi as the new Chief Financial Officer in October 2025 could also be viewed positively. Conversely, the disclosure of a Nasdaq delisting risk could negatively affect the company's reputation.

Fate Therapeutics, Inc. has a diverse ownership structure. Institutional investors hold a significant portion, with 280 institutional owners holding a total of 88,590,725 shares, collectively owning 67% of the company. Major institutional shareholders include Redmile Group, LLC, BlackRock, Inc., Vanguard Group Inc, Citadel Advisors Llc, Johnson & Johnson, Vestal Point Capital, LP, and Goldman Sachs Group Inc. Hedge funds account for 18% of the ownership. The general public holds a 14% ownership stake. Insiders collectively own approximately US$2.0 million worth of the company's shares.